Search
Now showing items 1-10 of 25
Genetic and perinatal risk factors for movement disorders
(North-West University, Potchefstroom Campus., 2018)
Movement disorders, such as Parkinson's disease (PD), Huntington's disease (HD) and cerebral palsy
(CP) are debilitating diseases with a great societal impact. These disorders are characterized by damage
to the basal ...
Screening of virtual libraries for monoamine oxidase inhibitors
(2013)
The traditional view of drug design is that a single drug should interact with a single
molecular target. As science progressed, there was an understanding that most drugs
interact with more than one target and that ...
Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase
(2014)
BACKGROUND AND RATIONALE
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder affecting the central nervous system, primarily, the substantia nigra. It is characterized by loss of dopaminergic ...
Synthesis of a series of novel 2- aminopyrimidine derivatives and their biological evaluation as adenosine receptor antagonists
(North-West University (South Africa) , Potchefstroom Campus, 2015)
Parkinson’s disease (PD) is a progressive, neurodegenerative movement disorder caused by a
substantial loss of dopamine in the striatum. This deficiency of dopamine in the brain results in the
typical motor symptoms such ...
An investigation of plant derived compounds as inhibitors of monoamine oxidase
(North-West University (South-Africa). Potchefstroom Campus, 2019)
Computational chemistry, among other things, elucidates possible drug-molecular target interactions when an algorithm is run on a molecular modelling program. Although it is just a projection of reality, it enables researchers ...
Synthesis and evaluation of 3,4-Dihydro-3-methyl-2(1H)-quinazolinone derivatives as monoamine oxidase inhibitors
(North-West University, Potchefstroom Campus, 2018)
Parkinson’s disease (PD) is an age related neurodegenerative disorder. Loss of dopamine from the striatum is responsible for the motor symptoms of PD. This loss of dopamine is due to degeneration of the neurons of the ...
Monoamine oxidase inhibition by indanone and benzoquinone analogues
(North-West University (South Africa) , Potchefstroom Campus, 2015)
Parkinson’s disease (PD) is a neurological disorder of which aging is the greatest risk factor. Over the next fifteen years, the number of persons affected by PD worldwide is expected to increase from 4.6 million to 9.3 ...
Monoamine oxidase inhibitory activities of heterocyclic chalcones
(2013)
Parkinson’s disease is the second most common age-related neurodegenerative disease after Alzheimer’s disease. The characteristic pathological feature of Parkinson’s disease is the loss of neurons in the substantia nigra ...
Synthesis and biological evaluation of 6-substituted coumaranone derivatives and related compounds as monoamine oxidase inhibitors
(2014)
Parkinson’s disease (PD) is an age related neurodegenerative disorder that presents with both motor and non-motor symptoms. The most common pathological characteristic of PD is the loss of the pigmented dopaminergic neurons ...
Syntheses of 8–(phenoxymethyl)caffeine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of the adenosine A2A receptor
(North-West University, 2013)
Background and rationale: Parkinson’s disease (PD) is a progressive, degenerative disorder of the central nervous system and is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. The ...